fda warns against compounded semaglutide of Overdoses With Compounded GLP-1s: Why doctors worry

Una vida fetal sin alteraciones, as como un periodo perinatal fisiolgicamente normal, obtienen como resultado un lactante/nio sano

2025;15(1):e7

In a large 2-year clinical trial involving 743 patients with a BMI of 2847, those taking orlistat (the active ingredient in Alli) lost, on average, 10.2% of their body weight during the first year, which is significantly more than the 6.1% lost by the placebo group. Patients who continued taking orlistat into the second year regained half as much weight as those who switched to placebo, demonstrating its effectiveness not only for weight loss but also for preventing weight regain. In addition to weight reduction, participants experienced improvements in cholesterol levels, glucose, and insulin concentrations. When used correctly alongside a balanced diet, Alli can be a powerful tool for achieving and maintaining weight loss

See you soon

Del Olmo-Garcia MI, Merino-Torres JF (2018) GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes